Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of intra-articular RTX-GRT7039 for knee osteoarthritis pain
NL-OMON51845Phase 3Completed
- Sponsor
- Grünenthal GmbH
- Start
- Feb 2023
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in knee osteoarthritis (OA) comparing RTX-GRT7039 with Placebo (2 arms). Started Feb 2023; status: completed.
02
Drugs
RTX-GRT7039
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NL-OMON51845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51845.